vs
Side-by-side financial comparison of NEXTNRG, INC. (NXXT) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
NEXTNRG, INC. is the larger business by last-quarter revenue ($23.0M vs $18.3M, roughly 1.3× ROCKWELL MEDICAL, INC.). ROCKWELL MEDICAL, INC. runs the higher net margin — -3.0% vs -116.1%, a 113.1% gap on every dollar of revenue. On growth, NEXTNRG, INC. posted the faster year-over-year revenue change (238.9% vs -25.6%). Over the past eight quarters, NEXTNRG, INC.'s revenue compounded faster (86.8% CAGR vs -10.1%).
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
NXXT vs RMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $18.3M |
| Net Profit | $-26.7M | $-554.0K |
| Gross Margin | 10.3% | 21.1% |
| Operating Margin | -107.2% | -2.2% |
| Net Margin | -116.1% | -3.0% |
| Revenue YoY | 238.9% | -25.6% |
| Net Profit YoY | -974.9% | 26.7% |
| EPS (diluted) | $1.30 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $18.3M | ||
| Q3 25 | $22.9M | $15.9M | ||
| Q2 25 | $19.7M | $16.1M | ||
| Q1 25 | $16.3M | $18.9M | ||
| Q4 24 | $6.8M | $24.7M | ||
| Q3 24 | $7.0M | $28.3M | ||
| Q2 24 | $7.4M | $25.8M | ||
| Q1 24 | $6.6M | $22.7M |
| Q4 25 | $-26.7M | $-554.0K | ||
| Q3 25 | $-14.1M | $-1.8M | ||
| Q2 25 | $-36.1M | $-1.5M | ||
| Q1 25 | $-8.8M | $-1.5M | ||
| Q4 24 | $-2.5M | $-756.0K | ||
| Q3 24 | $-10.6M | $1.7M | ||
| Q2 24 | $-5.6M | $343.0K | ||
| Q1 24 | $-2.7M | $-1.7M |
| Q4 25 | 10.3% | 21.1% | ||
| Q3 25 | 10.7% | 14.3% | ||
| Q2 25 | 8.0% | 15.6% | ||
| Q1 25 | 3.2% | 16.1% | ||
| Q4 24 | 2.5% | 14.7% | ||
| Q3 24 | 8.7% | 22.0% | ||
| Q2 24 | 7.4% | 17.6% | ||
| Q1 24 | 7.0% | 13.5% |
| Q4 25 | -107.2% | -2.2% | ||
| Q3 25 | -39.4% | -9.9% | ||
| Q2 25 | -156.2% | -8.4% | ||
| Q1 25 | -35.4% | -7.2% | ||
| Q4 24 | -62.8% | -2.1% | ||
| Q3 24 | -42.7% | 6.8% | ||
| Q2 24 | -35.2% | 2.0% | ||
| Q1 24 | -28.2% | -5.8% |
| Q4 25 | -116.1% | -3.0% | ||
| Q3 25 | -61.8% | -11.0% | ||
| Q2 25 | -183.3% | -9.3% | ||
| Q1 25 | -54.0% | -8.0% | ||
| Q4 24 | -36.6% | -3.1% | ||
| Q3 24 | -152.0% | 5.9% | ||
| Q2 24 | -76.0% | 1.3% | ||
| Q1 24 | -40.6% | -7.6% |
| Q4 25 | $1.30 | $-0.01 | ||
| Q3 25 | $-0.12 | $-0.05 | ||
| Q2 25 | $-0.30 | $-0.05 | ||
| Q1 25 | $-1.60 | $-0.04 | ||
| Q4 24 | $-3.72 | $-0.02 | ||
| Q3 24 | $-0.71 | $0.04 | ||
| Q2 24 | $-0.06 | $0.01 | ||
| Q1 24 | $-1.48 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-19.7M | $37.0M |
| Total Assets | $11.1M | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $10.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $12.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $15.7M | ||
| Q3 24 | — | $12.3M | ||
| Q2 24 | $306.8K | $11.9M | ||
| Q1 24 | $48.6K | $6.6M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $9.2M | — | ||
| Q3 24 | $725.3K | — | ||
| Q2 24 | $8.8M | — | ||
| Q1 24 | $7.3M | — |
| Q4 25 | $-19.7M | $37.0M | ||
| Q3 25 | $-16.3M | $37.0M | ||
| Q2 25 | $-13.6M | $30.4M | ||
| Q1 25 | $-5.6M | $31.5M | ||
| Q4 24 | $-12.7M | $32.6M | ||
| Q3 24 | $3.6M | $29.1M | ||
| Q2 24 | $-4.8M | $23.5M | ||
| Q1 24 | $-3.3M | $20.6M |
| Q4 25 | $11.1M | $57.1M | ||
| Q3 25 | $19.6M | $57.5M | ||
| Q2 25 | $25.5M | $52.6M | ||
| Q1 25 | $26.0M | $54.0M | ||
| Q4 24 | $22.4M | $59.2M | ||
| Q3 24 | $5.6M | $57.1M | ||
| Q2 24 | $22.4M | $53.0M | ||
| Q1 24 | $5.8M | $50.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-392.6K | $2.3M |
| Free Cash FlowOCF − Capex | — | $2.2M |
| FCF MarginFCF / Revenue | — | 12.0% |
| Capex IntensityCapex / Revenue | — | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-392.6K | $2.3M | ||
| Q3 25 | $-7.8M | $-1.3M | ||
| Q2 25 | $-564.5K | $1.8M | ||
| Q1 25 | $-5.8M | $-3.5M | ||
| Q4 24 | $-1.6M | $865.0K | ||
| Q3 24 | $3.6M | $4.3M | ||
| Q2 24 | $-7.0M | $1.4M | ||
| Q1 24 | $-1.4M | $-2.4M |
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $-1.5M | ||
| Q2 25 | — | $1.7M | ||
| Q1 25 | — | $-3.5M | ||
| Q4 24 | — | $470.0K | ||
| Q3 24 | — | $4.1M | ||
| Q2 24 | — | $1.2M | ||
| Q1 24 | — | $-2.5M |
| Q4 25 | — | 12.0% | ||
| Q3 25 | — | -9.6% | ||
| Q2 25 | — | 10.5% | ||
| Q1 25 | — | -18.8% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 14.4% | ||
| Q2 24 | — | 4.5% | ||
| Q1 24 | — | -11.1% |
| Q4 25 | — | 0.5% | ||
| Q3 25 | — | 1.4% | ||
| Q2 25 | — | 1.0% | ||
| Q1 25 | — | 0.3% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 0.7% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.57× | ||
| Q2 24 | — | 4.20× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NXXT
Segment breakdown not available.
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
